INVA — Innoviva, Inc. · 2026-09-04 · Verdict: WATCH · Conviction 3

Price $21.35 (screen row dated 2026-09-04; no live quote available) · Mkt cap $1.54B · EV $1.23B · EV/EBIT 7.5x · FCF yield 12.7% · Net cash $311.9M · ADV $13.4M Sources read: 10-K 2026-02-25 (Items 1, 1A, 7), 10-Q 2026-08-05, DEF 14A 2026-03-24, 8-Ks 2026-05-04, 2026-05-06, 2026-05-18 and 2026-08-05 (with EX-99.1 releases), Form 4s (trailing 12m). No earnings-call transcript was available in the bundle.

1. What the business actually does

Three separable things in one ticker (10-K 2025, Item 1). A royalty on two GSK inhalers, RELVAR/BREO ELLIPTA at 15% of the first $3.0 billion of annual global net sales and ANORO ELLIPTA at 6.5% to 10%; gross royalties were $250.3 million in 2025. A hospital critical-care and anti-infective business, Innoviva Specialty Therapeutics, built from the 2022 Entasis and La Jolla acquisitions and selling GIAPREZA, XACDURO, XERAVA, ZEVTERA and NUZOLVENCE; net product sales were $172.1 million in 2025, up 77% (10-K 2025, Item 7). And strategic healthcare stakes worth $669.5 million, $457.7 million of it one position, Armata Pharmaceuticals (Q2 2026 release). All run by 159 people.

2. Why it might be mispriced, and the honest limit

The edge case is a holding-company discount created by accounting noise. GAAP earnings are dominated by non-cash Armata marks, not operations: net income of $186.6 million in Q1 2026, then a net loss of $83.4 million in Q2, on operating income of $38.2 million and $50.9 million (Q1, Q2 2026 releases). Sum the parts instead: cash of $570.4 million plus investments of $669.5 million less the 2028 Notes is $978.9 million, $13.55 of the $21.35 price (10-Q Q2 2026).

The limit is that nobody is positioned to close the gap. The register is index and quant money, BlackRock 14.42% and Vanguard 10.69% among 36.7% held by four such firms, with all officers and directors at 2.01%. Sarissa Capital, the activist that built this structure, lost board representation and related-party status in May 2025 (DEF 14A 2026). The stock is 11.9% off its high and traded $16.67 to $22.28 during 2025 (10-K 2025, Item 1A): a chronic discount, not a fresh dislocation with a forced seller.

3. Unit economics and growth

The growth headline does not survive disaggregation. Q2 2026 revenue rose 19% to $119.6 million, but $10.6 million of the $19.3 million increase was license revenue jumping to $11.5 million from $0.9 million on new GARDP and Dr. Reddy's deals. Ex-U.S. product sales rose 133% to $15.2 million, but the XACDURO portion is supply to Zai Lab "billed at cost", which is why cost of products sold rose 111% to $22.3 million. Gross royalties fell 11% to $59.8 million, RELVAR/BREO down 13%, on U.S. pricing pressure (10-Q Q2 2026). The release calls royalties "stable" by comparing to the prior quarter rather than the prior year.

Good: U.S. product sales up 26% to $36.6 million. Bad: SG&A up 31% in Q2 to $34.6 million and 24% in H1. Strip the license delta and H1 operating income fell from $88.7 million to $76.1 million, down 14%, against reported $89.0 million versus $90.2 million. Annual operating income has now fallen two years running: $166.9 million in 2024, $163.7 million in 2025 (10-K 2025, Item 7). Trailing-twelve-month operating income is $162.6 million, $148.4 million ex-license.

4. Balance sheet and capital allocation

Debt is one instrument, $261.0 million of 2028 Notes at 2.125%. Two liabilities the screen's net-cash number omits: $59.9 million of long-term income tax payable and $67.3 million of other long-term liabilities, the latter holding the La Jolla deferred royalty obligation under which HCR takes up to 18% of worldwide GIAPREZA sales until 2031 or $225.0 million cumulative (10-Q Q2 2026). Federal NOLs of $497.7 million shelter cash taxes, subject to Section 382 limits (10-K 2025, Item 7).

Buybacks are real but small: 2,602,168 shares for $56.4 million since November 2025 against a $125.0 million authorization, 3.6% of the cap (Q2 2026 release). The 14.6% share-count rise the screen flags is an artifact of the 2025 Notes settling in August 2025: diluted shares were 84.5 million in H1 2026 against 84.3 million a year earlier, and the 10.7 million basic-to-diluted gap implies the 2028 Notes convert in the mid-$20s, capping upside there. Form 4s over twelve months show grants and withholding only, no open-market trades. Director Derek Small is founder and CEO of Syndeio, a portfolio holding (DEF 14A 2026).

5. Management: said versus did

The CEO guides to "at least $150 million in IST U.S. net product sales in 2026" (Q2 2026 release); H1 delivered $70.8 million, so H2 needs $79.2 million. The 2025 pledge to commercialize NUZOLVENCE in H2 2026, with or without a partner (10-K 2025, Item 7), was unresolved at the Q2 filing. And $55.0 million of fresh commitments went into the strategic portfolio in Q2, more than went into the stock management calls undervalued.

6. Valuation

Market cap is $1,542 million. Add the notes, tax payable and other long-term liabilities, subtract cash and investments at carrying value: the market pays about $691 million for a business earning $148.4 million of clean operating income, 4.7x, or 5.9x after tax at 21%. Haircut Armata by half and it is $920 million, 7.8x after tax.

Reverse DCF: at $691 million for $117 million of after-tax operating profit and a 10% discount rate, the price implies that stream shrinks about 7% a year forever, or 3% a year with a 50% Armata haircut.

Base (50%), $22.00: investments haircut 30%, operating business at 8x NOPAT of $117 million, cash and liabilities at face. Bear (25%), $14.54: royalties keep falling 10%, SG&A keeps outgrowing gross profit, NOPAT falls to $100 million at 6x, portfolio down 60%. Bull (25%), $29.64: U.S. products beat $150 million, royalties stabilize, 11x NOPAT, investments at carry. Probability-weighted $22.05 against $21.35, 3% upside.

7. Catalysts and timeline

The remaining $68.6 million of buyback authorization. The NUZOLVENCE partner-or-launch decision promised for H2 2026. Final ISP Fund wind-down distributions through April 2026. A royalty monetization, which GSK warns may need its consent (10-K 2025, Items 7 and 1A).

8. Risks and pre-registered kill criteria

Concentration is the main risk: one holding is 68% of the portfolio, and its mark moved $398M, $603M, $458M across three quarters. Generic FF/VI entry would take the royalty leg down hard (10-K 2025, Item 1A).

1. Gross GSK royalties fall more than 10% year over year for two more quarters.
2. 2026 IST U.S. net product sales land below the guided $150 million.
3. SG&A grows faster than gross profit for two more quarters.
4. Strategic investments carry below $450 million without a faster buyback.

9. Verdict and one-paragraph summary

WATCH, conviction 3. Innoviva holds $570M of cash and $670M of strategic investments against a $1.54B market cap, so you pay about $691M for a business earning $148M of operating profit: apparently a 4.7x asset-backed bargain. Two facts stop it being one. Operating profit is going backwards once you strip one-time license revenue, down 14% in H1, as a royalty stream falling 11% a year outruns a 26%-growing U.S. product business while SG&A grows 31%. And 68% of the hidden asset is one illiquid biotech stake whose mark swung from $398M to $603M to $458M in three quarters, so it is not money until sold. With index funds holding 37%, insiders 2%, the activist gone since May 2025 and the stock 12% below its high, nobody is positioned to force the discount closed. Fair value is about $22 against $21.35.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.